| CATEGORY: SMALL CAPS NEWS SECTOR: PHARMACEUTICALS & BIOTECHNOLOGY |
Plethora cheers PSD502 pain relief trial |
|
Tue 08 Aug 2006
|
LONDON (SHARECAST) - Plethora Solutions, which develops treatments for urological disorders, today reported “exciting” results from a study of its PSD502 pain relief treatment in patients undergoing skin grafts.
PSD502 is a metered-dose analgesic spray which reported positive results from a Phase II trial for the treatment of premature ejaculation in December last year.
But the group recognised that an additional commercial opportunity exists for the secondary use of PSD502 in the treatment of painful skin/membrane conditions where local application is possible.
As PSD502 contains no solvent, there is no initial stinging sensation and the metered-dose applicator makes dose adjustment extremely easy, said the company.
Dr De Mello, consultant in pain medicine at The Wythenshawe Burns Unit, Manchester, is currently performing the Proof of Principle study of PSD502 in patients who require skin grafting to treat burns.
Results have showed 75% of patients dosed have reported no pain or minimal pain at the donor site following treatment with PSD502.
Dr De Mello said, “The improvement in pain relief for patients who received PSD502 was considerable.”
|
|
| |
|
 |
Archived Stories |
 |
|
Front Page Stories |
|
|
